The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and ...

Investors are encouraged to read the Company's Annual Report on Form 10-K when it is filed with the Securities and Exchange ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment ...

RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK approval ...

Proteases are enzymes that catalyse hydrolysis of the peptide and isopeptide bonds that join amino acids within proteins (known as proteolysis). Proteases can also remove protein post ...